HMI-115

An antibody aimed at a hormone receptor. An antibody is a large protein designed to attach to a particular target. HMI-115 blocks the prolactin receptor, the receiving point for prolactin signals. Community interest centers on signaling inside hair follicles; a blood prolactin test does not establish whether this treatment would help someone's hair. Community explanation of local prolactin signaling versus blood levels (Community guide · Accessed 2026-09-30)

An injection candidate, with separate hair and endometriosis research. Forum discussions describe injections beneath the skin, rather than a daily scalp lotion. HMI-115 is neither a steroid nor a small peptide powder. Endometriosis is another development program; progress there does not itself demonstrate hair regrowth. ABS-201 is a separate candidate in the same receptor-targeting conversation, not another name for HMI-115. Injection route and sexual-side-effect questions (Secondhand community claim · Accessed 2026-09-30) · Hair community asks about the separate endometriosis program (Community discussion · Accessed 2026-09-30) · September 2026 underdose and ABS-201 debate (Community discussion · Accessed 2026-09-30)

Source context — Community explanation of local prolactin signaling versus blood levels: Mechanism/pipeline synthesis and opinion, not a first-person HMI-115 log. No prevalence or individual prediction inferred. Predictions for ABS-201, theoretical hormone/sexual benefits in replies and cross-drug superiority are not accepted as proven.

Source context — Injection route and sexual-side-effect questions: No participant's original sexual-effect statement inspected. Route claims conflict; beneath-skin route is confirmed separately against the registry, while scalp and direct-blood assertions are rejected. No general safety conclusion.

Source context — Hair community asks about the separate endometriosis program: Question and pipeline expectation, not a patient benefit report. Endometriosis trial milestones do not demonstrate hair efficacy. Linked Looksmax discussion and registration were not opened from this source.

Source context — September 2026 underdose and ABS-201 debate: Numbers repeat formal NCT06118866 arms; not human self-experiment doses. Claimed underdosing is secondhand interpretation of a linked video, which was not watched. Failure language is opinion, not an inspected trial result. Publication date from date-bearing search rendering; opened body displays relative times.

More density, with fewer daily treatment chores. The appeal is thicker coverage after a finite series of injections. In October 2023, moeman32, posting as a trial participant, described his hair filling out four months after the trial. One person's account does not establish a response rate or show that everyone can stop maintenance treatment. moeman32's post-trial filling-in account and replies (Personal report · Accessed 2026-09-30)

Photos are the center of the disagreement. The September 2023 discussion assembled public social photos rather than official trial images. Readers argued about wedding hair fibers, styling, whether existing hair looked thicker and whether bald areas had genuinely filled in. The fiber explanation was itself secondhand. This disagreement matters because lighting and cosmetic coverage can change perceived density without measuring new growth. Public-photo comparisons, wedding fibers and cure enthusiasm (Community discussion · Accessed 2026-09-30)

Disappointment is an opinion, not a nonresponder log. HairLossTalk's later pages contain readers who suspect failure, criticize the photos and ask why updates are scarce. Those posts document frustration; they do not describe those commenters receiving HMI-115 and failing to respond. The inspected sample lacks a verified first-person nonresponse account. HairLossTalk later disappointment and requests for updates (Community opinion · Accessed 2026-09-30)

The early human result was a small open-label study. Hope Medicine's January 2024 announcement described 12 men and four women treated over 24 weeks. The men's mean target-area count increased by 14 non-vellus hairs per square centimeter. With no placebo comparator, this sponsor-reported result does not establish complete regrowth or superiority to finasteride. Hope Medicine January 2024 Phase Ib announcement (Official context · Accessed 2026-09-30)

Source context — moeman32's post-trial filling-in account and replies: One self-identified trial participant, unverified assignment and measurements. His wife's account is secondhand; not used as an independent responder. His speculation about body size and animal doses is not accepted as dose rationale. Deleted replies and unexpanded reply branches remain inaccessible.

Source context — Public-photo comparisons, wedding fibers and cure enthusiasm: Independent readers discuss the same participant rather than independent treated users. Hair-fiber claim is secondhand. External galleries and wedding photos were not opened or republished; no participant identity inferred.

Source context — HairLossTalk later disappointment and requests for updates: Reader frustration and failure guesses, not reports of personal HMI-115 use or published Phase 2 efficacy. Does not authenticate allegations against a participant.

Source context — Hope Medicine January 2024 Phase Ib announcement: Commercial sponsor announcement, small uncontrolled study. Sponsor's safety and efficacy wording is not adopted as a safety assurance. PRNewswire reposts and community repetitions of these study numbers share the same origin budget.

Trial-origin amounts: 120 mg or 240 mg per administration. A September 2026 discussion repeats three trial arms: 120 mg every four weeks, 240 mg every four weeks, and 240 mg every two weeks. These are separate schedules for injections beneath the skin, not daily totals or a community-established dose range. The numbers originated in clinical research, even when repeated on Reddit. September 2026 underdose and ABS-201 debate (Community discussion · Accessed 2026-09-30) · Injection route and sexual-side-effect questions (Secondhand community claim · Accessed 2026-09-30)

Experimental access is not a consumer protocol. Trial participation, clinic claims and online product claims are different things. The community record does not establish a routine-use product, verified consumer supply or a peptide mixing recipe. Pipeline comparisons with ABS-201, PP405 and pyrilutamide are comparisons, not proven stacks.

Source context — September 2026 underdose and ABS-201 debate: Numbers repeat formal NCT06118866 arms; not human self-experiment doses. Claimed underdosing is secondhand interpretation of a linked video, which was not watched. Failure language is opinion, not an inspected trial result. Publication date from date-bearing search rendering; opened body displays relative times.

Source context — Injection route and sexual-side-effect questions: No participant's original sexual-effect statement inspected. Route claims conflict; beneath-skin route is confirmed separately against the registry, while scalp and direct-blood assertions are rejected. No general safety conclusion.

A circulated two-month photo claim. A May 2024 thread presents a purported trial image; a commenter says it came from WeChat and shows two months of treatment. Others welcome the apparent change or demand proof. The original log, assigned treatment and standardized photos were not available here, so two months is an unverified report, not an expected onset. Purported two-month WeChat photo and authenticity debate (Secondhand community claim · Accessed 2026-09-30)

Four months after a trial is one follow-up. Moeman32's continued filling-in report describes a post-treatment interval, not how long everyone keeps their gains. It does not establish a permanent effect or a typical relapse date. moeman32's post-trial filling-in account and replies (Personal report · Accessed 2026-09-30)

The four-year story comes from monkeys. HairLossTalk's original explainer repeats a patent-derived account of macaques retaining improvement years after treatment stopped. That animal follow-up helped create the excitement; it is not four years of documented human durability. HairLossTalk original HMI-115 explainer and patent-derived macaque follow-up (Community guide · Accessed 2026-09-30)

No community-measured human value in these accounts. These accounts supply no measured half-life. Injection spacing is a schedule, not the time for half the drug to leave circulation. ABS-201 timing cannot be transferred to HMI-115. September 2026 underdose and ABS-201 debate (Community discussion · Accessed 2026-09-30)

Source context — Purported two-month WeChat photo and authenticity debate: No original WeChat log, consented participant history, verified image date or blinded assignment obtained; neither image authenticity nor growth measured. Finasteride adverse accounts in this thread concern another drug. The purported post-HMI syndrome comment is explicitly identified as a game joke.

Source context — moeman32's post-trial filling-in account and replies: One self-identified trial participant, unverified assignment and measurements. His wife's account is secondhand; not used as an independent responder. His speculation about body size and animal doses is not accepted as dose rationale. Deleted replies and unexpanded reply branches remain inaccessible.

Source context — HairLossTalk original HMI-115 explainer and patent-derived macaque follow-up: Community compilation of patent and sponsor material. Four-year persistence retains animal/patent origin; original patent was not independently opened. No community human half-life or durable cure established. Promotional and historical launch predictions omitted.

Source context — September 2026 underdose and ABS-201 debate: Numbers repeat formal NCT06118866 arms; not human self-experiment doses. Claimed underdosing is secondhand interpretation of a linked video, which was not watched. Failure language is opinion, not an inspected trial result. Publication date from date-bearing search rendering; opened body displays relative times.

Six-month trial talk; no established repeat calendar. The participant said he would welcome another six months, while other commenters described a roughly six-month course followed by stopping. Wanting another course is not a report of actually repeating one. These accounts do not establish a consumer on/off cycle, maintenance interval or permanent one-course cure. moeman32's post-trial filling-in account and replies (Personal report · Accessed 2026-09-30)

Source context — moeman32's post-trial filling-in account and replies: One self-identified trial participant, unverified assignment and measurements. His wife's account is secondhand; not used as an independent responder. His speculation about body size and animal doses is not accepted as dose rationale. Deleted replies and unexpanded reply branches remain inaccessible.

Useful improvement versus a complete reversal. Readers reacting to the early hair-count announcement split between welcoming extra density and disappointment that it fell short of monkey-like regrowth. Some imagined adding HMI-115 to minoxidil. That is a proposed combination, not an inspected successful stack or a direct comparison between treatments. Readers debate the announced 14-hair result (Community discussion · Accessed 2026-09-30)

Experimental access is not a consumer protocol. Trial participation, clinic claims and online product claims are different things. The community record does not establish a routine-use product, verified consumer supply or a peptide mixing recipe. Pipeline comparisons with ABS-201, PP405 and pyrilutamide are comparisons, not proven stacks.

Proposed combinations: Some readers imagine adding minoxidil; the inspected accounts do not establish a successful combination. ABS-201, PP405 and pyrilutamide are comparison candidates, not proven stacks. [community]

Source context — Readers debate the announced 14-hair result: Opinions about sponsor results, not personal treatment logs. A search-returned version exposes dose and participant replies absent from the current opened body; those hidden passages were not used. Trial hair-count origin shares the Hope Medicine announcement source family.

Different from finasteride does not mean side-effect-free. A 2023 commenter repeats that a participant had no sexual side effects; this is secondhand and cannot establish general safety. The inspected accounts do not define a typical immediate feeling. Injection-site or whole-body effects and long-term tolerability need more than reassuring forum comments, and the prolactin pathway has roles beyond scalp hair. Injection route and sexual-side-effect questions (Secondhand community claim · Accessed 2026-09-30) · Community explanation of local prolactin signaling versus blood levels (Community guide · Accessed 2026-09-30)

Reproductive precautions and combinations remain important. The registered male hair trial required contraception and restricted other hair treatments. This does not establish safety during pregnancy or breastfeeding, or the safety of proposed combinations. Forum speculation is not an interaction assessment. NCT06118866 male androgenetic alopecia Phase 2 registry (Official context · Accessed 2026-09-30) · Readers debate the announced 14-hair result (Community discussion · Accessed 2026-09-30)

Experimental access is not a consumer protocol. Trial participation, clinic claims and online product claims are different things. The community record does not establish a routine-use product, verified consumer supply or a peptide mixing recipe. Pipeline comparisons with ABS-201, PP405 and pyrilutamide are comparisons, not proven stacks.

Source context — Injection route and sexual-side-effect questions: No participant's original sexual-effect statement inspected. Route claims conflict; beneath-skin route is confirmed separately against the registry, while scalp and direct-blood assertions are rejected. No general safety conclusion.

Source context — Community explanation of local prolactin signaling versus blood levels: Mechanism/pipeline synthesis and opinion, not a first-person HMI-115 log. No prevalence or individual prediction inferred. Predictions for ABS-201, theoretical hormone/sexual benefits in replies and cross-drug superiority are not accepted as proven.

Source context — NCT06118866 male androgenetic alopecia Phase 2 registry: Sponsor-submitted registry, not results publication. Completed status with no posted results does not establish failure or success. Registration uses subcutaneous arms; frozen catalog intramuscular/local metadata not changed by this proposal.

Source context — Readers debate the announced 14-hair result: Opinions about sponsor results, not personal treatment logs. A search-returned version exposes dose and participant replies absent from the current opened body; those hidden passages were not used. Trial hair-count origin shares the Hope Medicine announcement source family.